KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $69.7 million.

  • Amneal Pharmaceuticals' Change in Accured Expenses rose 4886.56% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.0 million, marking a year-over-year decrease of 5372.79%. This contributed to the annual value of $235.1 million for FY2024, which is 34896.24% up from last year.
  • Amneal Pharmaceuticals' Change in Accured Expenses amounted to $69.7 million in Q3 2025, which was up 4886.56% from $45.6 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Accured Expenses ranged from a high of $322.7 million in Q2 2022 and a low of -$150.5 million during Q1 2023
  • In the last 5 years, Amneal Pharmaceuticals' Change in Accured Expenses had a median value of $16.1 million in 2021 and averaged $11.0 million.
  • Over the last 5 years, Amneal Pharmaceuticals' Change in Accured Expenses had its largest YoY gain of 190586.74% in 2022, and its largest YoY loss of 82886.49% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$11.1 million in 2021, then crashed by 402.74% to -$55.9 million in 2022, then soared by 64.63% to -$19.8 million in 2023, then surged by 435.29% to $66.3 million in 2024, then grew by 5.27% to $69.7 million in 2025.
  • Its Change in Accured Expenses was $69.7 million in Q3 2025, compared to $45.6 million in Q2 2025 and -$112.6 million in Q1 2025.